Peptides vs HGH: What's the Difference and Why It Matters for Researchers

HGH (human growth hormone, also called somatropin) is a 191-amino acid protein produced by the anterior pituitary gland — a small gland at the base of the brain. It is the largest of the pituitary hormones. Growth hormone drives longitudinal growth in childhood and adolescence (via IGF-1 production in the liver), and continues throughout adult life to regulate body composition, metabolism, bone density, muscle mass, and cellular repair.

HGH is released from the pituitary in pulses — not continuously. The largest pulse occurs during slow wave sleep, roughly 60 to 90 minutes after falling asleep. These pulses are regulated by two hypothalamic hormones: GHRH (growth hormone releasing hormone), which stimulates release, and somatostatin, which inhibits it. The balance between these two hormones determines how much HGH is released and when.

HGH levels peak during the teenage growth years and decline gradually from early adulthood — roughly 14 percent per decade. This age related decline in growth hormone secretion is called somatopause and correlates with several aspects of the aging phenotype.

Growth hormone secretagogues are compounds that stimulate the pituitary gland to produce and release its own growth hormone — rather than replacing growth hormone from outside the body. They work upstream, triggering the natural release mechanism. The two main types are GHRH analogs (which mimic the hypothalamic "release" signal) and ghrelin mimetics (which act on a different receptor to amplify the GH pulse).

Examples include CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic). These compounds stimulate the pituitary to release its own GH — preserving the pulsatile release pattern and keeping the endocrine feedback loops intact. This is distinct from injecting synthetic HGH directly, which delivers a continuous or artificially timed dose that bypasses the regulatory system entirely.

The physiological distinction is significant: the body's own pulsatile release pattern is precisely regulated. Exogenous HGH injection delivers a pharmacological dose that is not pulsatile and is not regulated by the hypothalamic pituitary feedback loops. Secretagogues preserve these regulatory mechanisms.

The majority of research peptides have no direct connection to the growth hormone axis. BPC-157 works through the nitric oxide pathway and angiogenesis. GHK-Cu works through copper dependent enzyme activation and gene regulation. KPV works through melanocortin receptors. Selank works through GABA modulation. Semax works through BDNF upregulation. MOTS-c works through AMPK activation. SS-31 works through cardiolipin protection.

None of these mechanisms involve GH, GHRH, ghrelin, or IGF-1. The association of all research peptides with growth hormone reflects a misunderstanding of the field. Growth hormone secretagogues are one specific subcategory — perhaps 2 to 3 compounds in a catalog of dozens. They are not representative of the research peptide space as a whole.

For researchers, this means the question "does this peptide affect growth hormone?" has a compound specific answer — and for most compounds in this catalog, the answer is no.

In research settings where growth hormone biology is the research focus, secretagogues offer physiological advantages over direct HGH administration. The pulsatile release pattern appears to be important for the downstream biological effects: IGF-1 production, tissue repair responses, and metabolic effects are all regulated by the pattern of GH signaling, not just the total amount.

Administering exogenous HGH delivers large pharmacological doses that overwhelm the regulatory system — the pituitary stops its own production via negative feedback, the normal pulsatile pattern disappears, and IGF-1 levels are driven to continuous supraphysiological elevation rather than the regulated pulsatile pattern of normal physiology.

For research models where the question is "what does restoring normal GH pulsatility do to aging or metabolic outcomes?", secretagogues are more physiologically relevant tools than exogenous HGH. The research question determines which approach is appropriate.

HGH (somatropin) is a prescription only biologic drug in the United States, regulated by the FDA with approved indications including growth hormone deficiency, Turner syndrome, chronic kidney disease, and HIV related wasting. It is not approved for anti aging or performance enhancement uses, and its prescription for these purposes is off label.

GH secretagogue peptides (like CJC-1295 and Ipamorelin) are research compounds regulated as research chemicals — not as pharmaceutical drugs. They are not FDA approved drugs and are not legally sold as dietary supplements. They exist in the research compound category where they are available for laboratory and scientific research purposes.

This regulatory distinction reflects the different risk and efficacy evidence profiles of the two categories — HGH has decades of pharmaceutical development and clinical use; secretagogue peptides have a research compound profile.

Understanding the HGH-vs-peptide distinction clarifies several common confusions in the research community. Not all performance relevant peptides are HGH related. Not all GH related compounds have the same mechanism or risk profile. And the most impactful research peptides — by breadth of mechanism and depth of evidence — are largely unrelated to the GH axis.

For researchers entering this space, the clearest framework is mechanism first: understand what receptor or pathway each compound engages before trying to place it in a category. BPC-157's mechanism (angiogenesis via nitric oxide pathway) is entirely distinct from CJC-1295's mechanism (GHRH receptor activation), which is distinct from somatropin (direct GH receptor activation). These distinctions matter for research design and interpretation.

The research catalog provides mechanism information for each compound, allowing researchers to understand what they are actually studying.

For researchers interested in the growth hormone research space specifically, the secretagogue literature provides the most relevant starting point. For researchers interested in the broader peptide research landscape, the individual compound guides cover mechanisms and evidence bases that are independent of the GH axis for the majority of compounds.

The beginners guide to peptides article provides the foundational biology — amino acids, peptide bonds, receptor mechanisms — that contextualizes how all peptide compounds work relative to hormones like HGH.

The research catalog provides full specifications for each compound, with mechanism information that clarifies the GH relationship (or lack thereof) for each.